Advertisement

Picture BCNP Consultants European Chemistry Partnering 2018 Ffm Germany 600x60px
Document › Details

Agilent Technologies Inc.. (5/16/16). "Press Release: Agilent Technologies Reports Second-Quarter 2016 Results. Delivers Strong Quarter, Raises Full-Year Guidance". Santa Clara, CA.

Products Product analytical instrument
  Product 2 diagnostics (medical/biological)
Persons Person McMullen, Mike (Agilent 201409– COO + designated CEO for 3/15 before SVP + President Chemical Analysis Group)
  Person 2 Rodriguez, Alicia (Agilent 201506 VP Finance + Investor Relations)
     


Highlights:
> GAAP income from continuing operations of $91 million, or $0.28 per share

> Non-GAAP income from continuing operations of $145 million, or $0.44 per share(1)

> Revenue of $1.02 billion; core revenue growth of 8.0 percent(2)

> Raises fiscal year guidance for core revenue growth(2), adjusted non-GAAP operating margin(3), non-GAAP earnings per share(4) and operating cash flow

> Fiscal year 2016 revenue guidance of $4.16 billion to $4.18 billion, and non-GAAP earnings guidance of $1.88 to $1.92 per share(4)


Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.02 billion, up 6 percent year over year (up 8 percent on a core basis(2)) for the second fiscal quarter ended April 30, 2016.

Second-quarter GAAP income from continuing operations was $91 million, or $0.28 per share. Last year's second-quarter GAAP income from continuing operations was $92 million, or $0.27 per share.

During the second quarter, Agilent had intangible amortization of $40 million, transformation costs of $10 million, acquisition and integration costs of $12 million, and $2 million of other costs. Excluding those items, and a tax benefit of $10 million, Agilent reported second-quarter adjusted income from continuing operations of $145 million, $0.44 per share(1).

Agilent's adjusted operating margin was 19.4 percent(3) for the second quarter, up 110 basis points over a year ago.

"Agilent delivered another strong quarter," said Mike McMullen, Agilent president and CEO. "Revenue and earnings per share exceeded our guidance range. We saw broad growth across most of our portfolio and end markets."

"We continue to execute on our strategy to drive sustainable growth, expand operating margins and provide long-term value to our shareholders," he added.

Second-quarter revenue of $495 million from Agilent's Life Sciences and Applied Markets Group (LSAG) increased 5 percent year over year (up 8 percent on a core basis(2)), led by strong growth in pharma, food and environmental markets. LSAG's Q2 operating margin was 19.0 percent.

Second-quarter revenue of $346 million from the Agilent CrossLab Group (ACG) grew 8 percent year over year (up 10 percent on a core basis(2)). Both services and consumables continued to see solid growth worldwide. ACG's operating margin was 21.5 percent for the quarter.

Second-quarter revenue of $178 million from Agilent's Diagnostics and Genomics Group (DGG) increased 5 percent against a tough year-over-year compare (also up 5 percent on a core basis(2)), reflecting strength in its diagnostics and genomics businesses. DGG's operating margin for the quarter was 15.0 percent.

Agilent expects third-quarter 2016 revenue in the range of $1.03 billion to $1.05 billion. Third-quarter non-GAAP earnings are expected to be in the range of $0.45 to $0.47 per share(4).

For fiscal year 2016, Agilent expects revenue of $4.16 billion to $4.18 billion and non-GAAP earnings of $1.88 to $1.92 per share(4). The guidance is based on April 29, 2016 exchange rates.

Agilent is also raising its full-year operating cash flow guidance from $650 million to $740 million. There is no change to the capital expenditure guidance of $140 million.


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenue of $4.04 billion in fiscal 2015. The company employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.

Agilent's management will present more details about its second-quarter FY2016 financial results on a conference call with investors today at 1:30 p.m. PT. This event will be webcast live in listen-only mode. Listeners may log on at www.investor.agilent.com and select "Q2 2016 Agilent Technologies Inc. Earnings Conference Call" in the "News & Events Calendar of Events" section. The webcast will remain available on the company's website for 90 days.

Additional information regarding financial results can be found at www.investor.agilent.com by selecting "Financial Results" in the "Financial Information" section.

A telephone replay of the conference call will be available at approximately 4:30 p.m. PT today through May 23 by dialing +1 855 859 2056 (or +1 404 537 3406 from outside the United States) and entering passcode 93209349.


Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent's future revenue, earnings and profitability; planned new products; market trends; the future demand for the company's products and services; customer expectations; and revenue and non-GAAP earnings guidance for the third quarter and full fiscal year 2016. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers' businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.

In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on our operations, our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of our supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended Jan. 31, 2016. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

(1) Non-GAAP income from continuing operations and non-GAAP income from continuing operations per share exclude primarily the impacts of acquisition and integration costs, transformation initiatives, business exit and divestiture costs, and non-cash intangibles amortization. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or cannot be expected to occur again with any regularity or predictability. A reconciliation between non-GAAP income from continuing operations and GAAP income from continuing operations is set forth on page 6 of the attached tables along with additional information regarding the use of this non-GAAP measure.

(2) Core revenue growth excludes the impact of currency, the NMR business and acquisitions and divestitures within the past 12 months. Core revenue is a non-GAAP measure. Core revenue growth as projected for the full fiscal year 2016 excludes amounts pertaining to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. A reconciliation between Q2 FY16 GAAP revenue and core revenue is set forth on page 8 of the attached tables along with additional information regarding the use of this non-GAAP measure.

(3) Adjusted non-GAAP operating margin is a non-GAAP measure and excludes primarily the impacts of acquisition and integration costs, transformation initiatives, business exit and divestiture costs, and non-cash intangibles amortization in addition to the costs related to services that Agilent is providing to Keysight post separation. Adjusted non-GAAP operating margin as projected for the full fiscal year 2016 excludes amounts pertaining to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. A reconciliation for Q2 FY16 is set forth on page 9 of the attached tables along with additional information regarding the use of this non-GAAP measure.

(4) Non-GAAP earnings per share as projected for Q3 FY16 and full fiscal year 2016 excludes primarily the future impact of acquisition and integration costs, pension curtailment gain, business exit and divestiture costs and non-cash intangibles amortization. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or cannot be expected to occur again with any regularity or predictability. Most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. Therefore, no reconciliation to GAAP amounts has been provided. Future amortization of intangibles is expected to be approximately $38 million per quarter.

# # #


Download Financial Statements for Second-Quarter Fiscal 2016

Download Financial Statements Financial Tables (169KB) [ www.agilent.com/about/newsroom/presrel/2016/q2fy16tables.xls ]


Contacts

Editorial Contact:

Russell Lee
+1 408 345 8419
russell_lee@agilent.com

Investor Contact:

Alicia Rodriguez
+1 408 345 8948
alicia_rodriguez@agilent.com

   
Record changed: 2016-07-02

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px

More documents for Agilent (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture BCNP Consultants European Chemistry Partnering 2018 Ffm Germany 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BCNP Consultants European Chemistry Partnering 2018 Ffm 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture BCNP Consultants European Chemistry Partnering 2018 Ffm 120x180px